NovoCure price to sales ratio NVCR

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 2.4×
10-year median: 13.1×
Against its 10-year history: 8th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.8× to 43.4×
Peer median: 3.4×

NovoCure's price to sales ratio is 2.4× as of Oct 23, 2026.

That is below its ten-year median of 13.1×, lower than on 92% of days in the last ten years.

Over that time it ranged from 1.8× in Feb 2026 to 43.4× in Jun 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.4×	1.8×	3.1×
2025	2.4×	1.9×	5.7×
2024	5.7×	2.5×	6.3×
2023	3.2×	2.4×	21.1×
2022	14.2×	11.3×	17.1×
2021	14.3×	14.3×	43.4×
2020	39.2×	15.6×	39.2×
2019	26.9×	13.5×	31.2×
2018	13.2×	9.8×	22.4×
2017	11.8×	7.2×	16.1×
2016	10.5×	8.9×	15.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.

Company	Price to sales ratio
NVCRNovoCure	2.4×
LMATLemaitre Vascular	7.4×
EYENational Vision	0.7×
INSPInspire Medical Systems	2.3×
CDRECadre	1.9×
UFPTUFP Technologies	3.6×
BVSBioventus	2.2×
STAAStaar Surgical	3.3×
IRMDIradimed	12.7×
ATRCAtriCure	5.3×
WRBYWarby Parker	3.5×
Peer median	3.4×

Where NovoCure ranks

#59of 116Medical instruments and supplies stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on NovoCure

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.